CS Diagnostics is a pre-revenue medical device company focused on oncology. Its core product, CS Protect-Hydrogel, is a proprietary hydrogel device designed to improve outcomes and reduce side effects in cancer treatment. The product has not yet received regulatory approval and has not been commercialized. CS Diagnostics also holds U.S. distribution rights for MEDUSA-SDP, a separate product through which the company expects to earn a 5% royalty on U.S. sales, though this arrangement has not commenced. The company has generated no product revenue; its only reported revenue in FY25 was $204K in fixed payments from affiliated entities under a related-party agreement, not from customer sales. CS Diagnostics targets the EU and U.S. oncology markets, estimating an addressable patient population of roughly 385,400 annually, with pricing projected at roughly €1,100–€1,300 per unit in Europe and ~$2,000 in the U.S. The company's balance sheet is dominated by ~$499M in intangible assets representing the carrying value of the CS Protect-Hydrogel intellectual property, derived from a discounted cash flow model built on speculative assumptions. The company holds only $6,813 in cash and relies on affiliated entities for operating support, with near-term survival dependent on continued affiliate funding and external capital raises, including a Share Subscription Facility with stated capacity of up to $50M.